InhaleRx (ASX:IRX) formally executed a study order with iNGENu CRO as the contract research organization to oversee its phase one clinical trial of IRX-616a, a drug candidate for panic disorder, according to a Thursday Australian bourse filing.
The study is a randomized, double-blind, placebo-controlled, single ascending dose trial seeking to evaluate the pharmacokinetics, safety, and tolerability of the IRX-616a cannabidiol inhaler in healthy volunteers, the filing said.
The firm plans to procure the manufacturing of the drug candidate and finalize all documentation for a human research ethics committee approval, per the filing.
InhaleRx's shares jumped over 22% in recent trading on Thursday, earlier hitting an all-time low.
Price (AUD): $0.02, Change: $+0.0040, Percent Change: +22.22%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。